Skip to content

Study · Case report or series · n = 1 · 2025

2 results

Coincidence of Autoimmune Diabetes Mellitus and Familial Partial Lipodystrophy.

Krienke M, Schmidt HHJ, Buettner J, Tan S, Schumann I, Miehle K

JCEM case reports10 Nov 2025

PMID41221014 (opens in a new tab)PMCIDPMC12598280 (opens in a new tab)DOI10.1210/jcemcr/luaf265 (opens in a new tab)PepBankPUB-41221014
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with type 1 diabetes and familial partial lipodystrophy, insulin resistance improved during semaglutide treatment added to insulin.

    In plain wordsIn one woman with type 1 diabetes and a rare fat-tissue disorder, insulin resistance improved when semaglutide was added to insulin.

    Peptide
    Semaglutide
    Outcome
    DecreaseInsulin resistance
    Study

    n = 1

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Insulin resistance and hyperphagia improved during treatment with the glucagon-like peptide 1-receptor agonist semaglutide in addition to insulin therapy.
    1 context sentence
    Summary · context
    We identified a female patient with the initial diagnosis of autoantibody-positive type 1 diabetes who developed severe insulin resistance with daily insulin doses up to 300 IU/d, acanthosis nigricans, polycystic ovary syndrome, hyperphagia, myalgia, and dyslipidemia.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with type 1 diabetes and familial partial lipodystrophy, hyperphagia improved during semaglutide treatment added to insulin.

    In plain wordsIn one woman with type 1 diabetes and a rare fat-tissue disorder, excessive eating improved when semaglutide was added to insulin.

    Peptide
    Semaglutide
    Outcome
    DecreaseHyperphagia
    Study

    n = 1

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Insulin resistance and hyperphagia improved during treatment with the glucagon-like peptide 1-receptor agonist semaglutide in addition to insulin therapy.
    1 context sentence
    Summary · context
    We identified a female patient with the initial diagnosis of autoantibody-positive type 1 diabetes who developed severe insulin resistance with daily insulin doses up to 300 IU/d, acanthosis nigricans, polycystic ovary syndrome, hyperphagia, myalgia, and dyslipidemia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.